TD2 Oncology
TD2 Oncology is a leader in preclinical oncology studies, advancing novel therapies through customized programs. Our expertise includes CDX, PDX, syngeneic, and humanized models, along with advanced immuno-oncology systems. We integrate biomarker strategy, flow cytometry, PK/PD, and efficacy assessments to deliver actionable insights that guide development. With deep capabilities in ADCs and cell and gene therapies such as CAR-T, we help sponsors make confident decisions on program progression. Beyond preclinical research, TD2 provides clinical trial management to ensure efficient, high-quality execution from IND submission through early phase oncology trials.
